-
Mashup Score: 92Telehealth Geriatric Assessment and Supportive Care Intervention (GAIN-S) Program: A Randomized Clinical Trial - 1 month(s) ago
Background: Older patients with cancer face challenges in accessing high-quality cancer care, especially in resource-limited settings. We assessed the impact of a telehealth-adapted Geriatric Assessment–Guided Intervention (GAIN-S) among older Brazilians with metastatic cancer. Patient and Methods: This randomized clinical trial enrolled adults aged ≥65 years with metastatic cancer between June 2022 and July 2023. Patients were randomly assigned (1:1) to receive either usual care or GAIN-S. In the GAIN-S arm, a multidisciplinary team (MDT) developed an intervention plan based on impairments identified through geriatric assessment (GA). The plan included MDT discussions and targeted referrals to psychiatry, social services, nutrition, supportive care, and certified fitness training over a 3-month period. Assessments were conducted at baseline and at 3 months. The primary outcome was change in physical function, measured by instrumental activities of daily living (IADL) at 3 months. Seco
Source: jnccn.orgCategories: General Medicine NewsTweet
-
Mashup Score: 17
Experts convened at the NCCN 2025 Annual Conference to discuss the rapidly evolving landscape of artificial intelligence (AI) in cancer care, focusing on governance, opportunities, and challenges. Moderated by Clifford S. Goodman, PhD, the panel explored what makes AI unique in oncology, citing data intensity, multimodal data integration, the rapid pace of drug discovery, and high patient engagement. Current applications highlighted include administrative task reduction through record summarization and ambient listening tools, which are already improving efficiency and reducing clinician burden. Looking ahead, panelists foresee AI playing significant roles in precision medicine, predicting protein folding for drug design, optimizing treatment plans, improving remote patient monitoring for proactive care, enabling cancer interception through early detection, and potentially driving research discovery. However, challenges such as model accuracy, data quality, regulatory lag, ensuring tru
Source: jnccn.orgCategories: General Medicine NewsTweet-
Artificial Intelligence in Cancer Care: Opportunities, Challenges, and Governance https://t.co/qD0DzJP971 @JNCCN @oncologynursing @OncoAlert
-
-
Mashup Score: 17
Experts convened at the NCCN 2025 Annual Conference to discuss the rapidly evolving landscape of artificial intelligence (AI) in cancer care, focusing on governance, opportunities, and challenges. Moderated by Clifford S. Goodman, PhD, the panel explored what makes AI unique in oncology, citing data intensity, multimodal data integration, the rapid pace of drug discovery, and high patient engagement. Current applications highlighted include administrative task reduction through record summarization and ambient listening tools, which are already improving efficiency and reducing clinician burden. Looking ahead, panelists foresee AI playing significant roles in precision medicine, predicting protein folding for drug design, optimizing treatment plans, improving remote patient monitoring for proactive care, enabling cancer interception through early detection, and potentially driving research discovery. However, challenges such as model accuracy, data quality, regulatory lag, ensuring tru
Source: jnccn.orgCategories: General Medicine NewsTweet-
Artificial Intelligence in Cancer Care: Opportunities, Challenges, and Governance https://t.co/qD0DzJP971 @JNCCN @oncologynursing @OncoAlert
-
-
Mashup Score: 10Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma - 2 month(s) ago
The last 2 decades have seen a paradigm shift in the treatment landscape of metastatic gastric and gastroesophageal adenocarcinomas, with most of the progress occurring in recent years. Following the pivotal ToGA trial and the approval of trastuzumab for HER2-positive disease, the search for biomarkers has advanced exponentially. Currently, therapies are guided by key biomarkers such as HER2, PD-L1, dMMR/MSI-H, and, most recently, CLDN18.2. FGFR2b is emerging as a potential biomarker in this field. The most recent addition to this therapeutic arsenal is zolbetuximab. Two recent phase III trials have demonstrated survival benefits with the addition of zolbetuximab to frontline chemotherapy. A number of other biomarker-driven clinical trials are in progress, investigating new targeted agents that are expected to further transform the management of gastric or gastroesophageal adenocarcinoma.
Source: jnccn.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @jamesyuhemonc: Honored to share our @JNCCN review on biomarker-driven approaches for Metastatic Gastric Cancer https://t.co/hzxbpn59P5…
-
-
Mashup Score: 10Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma - 2 month(s) ago
The last 2 decades have seen a paradigm shift in the treatment landscape of metastatic gastric and gastroesophageal adenocarcinomas, with most of the progress occurring in recent years. Following the pivotal ToGA trial and the approval of trastuzumab for HER2-positive disease, the search for biomarkers has advanced exponentially. Currently, therapies are guided by key biomarkers such as HER2, PD-L1, dMMR/MSI-H, and, most recently, CLDN18.2. FGFR2b is emerging as a potential biomarker in this field. The most recent addition to this therapeutic arsenal is zolbetuximab. Two recent phase III trials have demonstrated survival benefits with the addition of zolbetuximab to frontline chemotherapy. A number of other biomarker-driven clinical trials are in progress, investigating new targeted agents that are expected to further transform the management of gastric or gastroesophageal adenocarcinoma.
Source: jnccn.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @jamesyuhemonc: Honored to share our @JNCCN review on biomarker-driven approaches for Metastatic Gastric Cancer https://t.co/hzxbpn59P5…
-
-
Mashup Score: 10Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma - 2 month(s) ago
The last 2 decades have seen a paradigm shift in the treatment landscape of metastatic gastric and gastroesophageal adenocarcinomas, with most of the progress occurring in recent years. Following the pivotal ToGA trial and the approval of trastuzumab for HER2-positive disease, the search for biomarkers has advanced exponentially. Currently, therapies are guided by key biomarkers such as HER2, PD-L1, dMMR/MSI-H, and, most recently, CLDN18.2. FGFR2b is emerging as a potential biomarker in this field. The most recent addition to this therapeutic arsenal is zolbetuximab. Two recent phase III trials have demonstrated survival benefits with the addition of zolbetuximab to frontline chemotherapy. A number of other biomarker-driven clinical trials are in progress, investigating new targeted agents that are expected to further transform the management of gastric or gastroesophageal adenocarcinoma.
Source: jnccn.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @jamesyuhemonc: Honored to share our @JNCCN review on biomarker-driven approaches for Metastatic Gastric Cancer https://t.co/hzxbpn59P5…
-
-
Mashup Score: 10Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma - 2 month(s) ago
The last 2 decades have seen a paradigm shift in the treatment landscape of metastatic gastric and gastroesophageal adenocarcinomas, with most of the progress occurring in recent years. Following the pivotal ToGA trial and the approval of trastuzumab for HER2-positive disease, the search for biomarkers has advanced exponentially. Currently, therapies are guided by key biomarkers such as HER2, PD-L1, dMMR/MSI-H, and, most recently, CLDN18.2. FGFR2b is emerging as a potential biomarker in this field. The most recent addition to this therapeutic arsenal is zolbetuximab. Two recent phase III trials have demonstrated survival benefits with the addition of zolbetuximab to frontline chemotherapy. A number of other biomarker-driven clinical trials are in progress, investigating new targeted agents that are expected to further transform the management of gastric or gastroesophageal adenocarcinoma.
Source: jnccn.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @jamesyuhemonc: Honored to share our @JNCCN review on biomarker-driven approaches for Metastatic Gastric Cancer https://t.co/hzxbpn59P5…
-
-
Mashup Score: 8Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma - 2 month(s) ago
The last 2 decades have seen a paradigm shift in the treatment landscape of metastatic gastric and gastroesophageal adenocarcinomas, with most of the progress occurring in recent years. Following the pivotal ToGA trial and the approval of trastuzumab for HER2-positive disease, the search for biomarkers has advanced exponentially. Currently, therapies are guided by key biomarkers such as HER2, PD-L1, dMMR/MSI-H, and, most recently, CLDN18.2. FGFR2b is emerging as a potential biomarker in this field. The most recent addition to this therapeutic arsenal is zolbetuximab. Two recent phase III trials have demonstrated survival benefits with the addition of zolbetuximab to frontline chemotherapy. A number of other biomarker-driven clinical trials are in progress, investigating new targeted agents that are expected to further transform the management of gastric or gastroesophageal adenocarcinoma.
Source: jnccn.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @jamesyuhemonc: Honored to share our @JNCCN review on biomarker-driven approaches for Metastatic Gastric Cancer https://t.co/hzxbpn59P5…
-
-
Mashup Score: 8Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma - 2 month(s) ago
The last 2 decades have seen a paradigm shift in the treatment landscape of metastatic gastric and gastroesophageal adenocarcinomas, with most of the progress occurring in recent years. Following the pivotal ToGA trial and the approval of trastuzumab for HER2-positive disease, the search for biomarkers has advanced exponentially. Currently, therapies are guided by key biomarkers such as HER2, PD-L1, dMMR/MSI-H, and, most recently, CLDN18.2. FGFR2b is emerging as a potential biomarker in this field. The most recent addition to this therapeutic arsenal is zolbetuximab. Two recent phase III trials have demonstrated survival benefits with the addition of zolbetuximab to frontline chemotherapy. A number of other biomarker-driven clinical trials are in progress, investigating new targeted agents that are expected to further transform the management of gastric or gastroesophageal adenocarcinoma.
Source: jnccn.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @jamesyuhemonc: Honored to share our @JNCCN review on biomarker-driven approaches for Metastatic Gastric Cancer https://t.co/hzxbpn59P5…
-
-
Mashup Score: 2Discussing Validation of the PREDICT Prognostication Tool in Patients With Breast Cancer - 2 month(s) ago
“Discussing Validation of the PREDICT Prognostication Tool in Patients With Breast Cancer” published on Oct 2023 by National Comprehensive Cancer Network.
Source: jnccn.orgCategories: General Medicine NewsTweet-
Discussing Validation of the PREDICT Prognostication Tool in Patients With Breast Cancer https://t.co/BF3wy8FQqN via @paulpharoah
-
📢 Just published in @JNCCN ! Our RCT shows that a telehealth GA & #SuppCare Intervention (GAIN-S) improved physical function, mood & QoL in older Brazilians with metastatic cancer @WilliamDale_MD @EnriqueSoto8 @Areejmd @RyanNipp https://t.co/21eTydfBP0 https://t.co/I1BxU7v6tm